EGFR and neoplasm: In conclusion, in patients with EGFR-mutant NSCLC enrolled in this study, the presence/absence of tumor PD-L1 expression was associated with the PFS and the proportion of acquisition of the T790M mutation of EGFR after first-line treatment with EGFR-TKIs.